CSIMarket
 


Cytokinetics Incorporated  (CYTK)
Other Ticker:  
 

Cytokinetics Incorporated's Working Capital Ratio

CYTK's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 9.28 below Cytokinetics Incorporated average.

Within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Working Capital Ratio than Cytokinetics Incorporated in third quarter 2023. While Working Capital Ratio total ranking has improved so far during the III Quarter 2023 to 112, from total ranking in the second quarter 2023 at 229.

Explain Working Capital Ratio
How much in Current Assets CYTK´s has?
What is the value of CYTK´s Current Liabilities?


CYTK Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 0.08 % -4.99 % 16.43 % 25.95 % -10.17 %
Y / Y Current Assets Change -36.51 % -2.6 % 9.16 % 48.45 % 78.66 %
Working Capital Ratio MRQ 9.28 11.75 11.17 11.08 14.63
CYTK's Total Ranking # 112 # 229 # 149 # 151 # 375
Seq. Current Liabilities Change 21.18 % -18.11 % -15.09 % 18.78 % 15.04 %
Seq. Current Assets Change -4.29 % -13.82 % -14.41 % -10.07 % 46.83 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 23
Healthcare Sector # 40
Overall Market # 112


Working Capital Ratio Statistics
High Average Low
23.3 9.3 1.85
(Jun 30 2012)   (Sep 30 2013)




Financial Statements
Cytokinetics Incorporated's Current Liabilities $ 60 Millions Visit CYTK's Balance sheet
Cytokinetics Incorporated's Current Assets $ 561 Millions Visit CYTK's Balance sheet
Source of CYTK's Sales Visit CYTK's Sales by Geography


Cumulative Cytokinetics Incorporated's Working Capital Ratio

CYTK's Working Capital Ratio for the trailling 12 Months

CYTK Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 0.08 % -4.99 % 16.43 % 25.95 % -10.17 %
Y / Y Current Assets TTM Growth -36.51 % -2.6 % 9.16 % 48.45 % 78.66 %
Working Capital Ratio TTM 10.79 12.12 12.06 12.25 11.9
Total Ranking TTM # 3945 # 2286 # 4064 # 108 # 433
Seq. Current Liabilities TTM Growth 21.18 % -18.11 % -15.09 % 18.78 % 15.04 %
Seq. Current Assets TTM Growth -4.29 % -13.82 % -14.41 % -10.07 % 46.83 %


On the trailing twelve months basis Due to growth in Current Liabilities in the III Quarter 2023 to $60.49 millions, cumulative Working Capital Ratio decreased to 10.79 above the CYTK average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 511 other companies have achieved higher Working Capital Ratio than Cytokinetics Incorporated. While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 2286 to 3945.

Explain Working Capital Ratio
How much in Current Assets CYTK´s has?
What is the value of CYTK´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 512
Healthcare Sector # 1047
Within the Market # 3945


trailing twelve months Working Capital Ratio Statistics
High Average Low
13.16 7.3 2.73
(Mar 31 2021)   (March 31, 2014)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Belite Bio Inc  24.76 $ 89.940  Millions$ 3.633  Millions
Janux Therapeutics Inc   24.55 $ 355.195  Millions$ 14.471  Millions
Gh Research Plc  24.49 $ 164.089  Millions$ 6.701  Millions
Bright Minds Biosciences Inc   24.26 $ 5.218  Millions$ 0.215  Millions
Design Therapeutics Inc   23.77 $ 294.543  Millions$ 12.390  Millions
Lixte Biotechnology Holdings Inc   23.67 $ 5.235  Millions$ 0.221  Millions
Diamedica Therapeutics Inc   22.91 $ 47.886  Millions$ 2.090  Millions
Terns Pharmaceuticals Inc   22.38 $ 270.455  Millions$ 12.087  Millions
Tyra Biosciences Inc   22.14 $ 224.630  Millions$ 10.147  Millions
Cyteir Therapeutics Inc   21.89 $ 130.643  Millions$ 5.969  Millions
Ars Pharmaceuticals Inc   21.87 $ 244.466  Millions$ 11.180  Millions
Eledon Pharmaceuticals Inc   21.73 $ 62.991  Millions$ 2.899  Millions
Astria Therapeutics inc   21.53 $ 191.466  Millions$ 8.894  Millions
Xenon Pharmaceuticals Inc   21.46 $ 531.008  Millions$ 24.744  Millions
Sagimet Biosciences inc   20.79 $ 102.816  Millions$ 4.946  Millions
Acasti Pharma Inc   20.68 $ 28.887  Millions$ 1.397  Millions
Akero Therapeutics Inc   20.25 $ 575.979  Millions$ 28.447  Millions
Tenax Therapeutics Inc   19.73 $ 11.883  Millions$ 0.602  Millions
Mineralys Therapeutics Inc   19.59 $ 265.375  Millions$ 13.543  Millions
Pliant Therapeutics Inc   19.50 $ 534.335  Millions$ 27.395  Millions
Stoke Therapeutics Inc   19.47 $ 230.019  Millions$ 11.811  Millions
Eqrx Inc   19.38 $ 1,235.139  Millions$ 63.726  Millions
Ideaya Biosciences Inc   19.37 $ 482.182  Millions$ 24.893  Millions
Pmv Pharmaceuticals Inc   19.16 $ 205.296  Millions$ 10.716  Millions
Savara Inc   18.98 $ 170.096  Millions$ 8.963  Millions
Medicinova Inc   18.92 $ 52.996  Millions$ 2.802  Millions
Immuneering Corporation  18.90 $ 100.583  Millions$ 5.321  Millions
Nextcure Inc   18.72 $ 122.684  Millions$ 6.552  Millions
Fulcrum Therapeutics Inc   18.65 $ 262.490  Millions$ 14.075  Millions
Compass Pathways Plc  18.55 $ 284.806  Millions$ 15.350  Millions

Date modified: 2023-11-06T19:11:58+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com